Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network.

To the Editor: We report the occurrence of uveitis and pseudojaundice in patients with AIDS who were receiving the combination of clarithromycin, rifabutin, and ethambutol for the treatment of Mycobacterium avium complex bacteremia. We are conducting a prospective, randomized, multicenter study comparing two oral multidrug regimens for the treatment of M. avium complex bacteremia in adults with AIDS. As of November 5, 1993, 119 patients had entered this study, 59 of whom were assigned to receive a regimen consisting of 1000 mg of clarithromycin twice daily, 600 mg of rifabutin daily, and 15 mg of ethambutol per kilogram of body . . .